Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.93M Sell
4,861
-109
-2% -$31K 0.01% 705
2026
Q1
$862K Buy
4,970
+1,926
+63% +$395K 0.01% 948
2025
Q4
$780K Sell
3,044
-710
-19% -$186K 0.01% 924
2025
Q3
$977K Buy
3,754
+530
+16% +$139K 0.01% 840
2025
Q2
$788K Buy
3,224
+768
+31% +$191K 0.01% 834
2025
Q1
$650K Buy
2,456
+729
+42% +$197K 0.01% 895
2024
Q4
$438K Buy
1,727
+310
+22% +$83.1K 0.01% 1019
2024
Q3
$449K Buy
1,417
+277
+24% +$98.6K 0.01% 984
2024
Q2
$426K Buy
1,140
+31
+3% +$10.5K 0.01% 977
2024
Q1
$385K Sell
1,109
-506
-31% -$192K 0.01% 924
2023
Q4
$739K Sell
1,615
-3,130
-66% -$1.54M 0.02% 647
2023
Q3
$2.31M Buy
+4,745
New +$2.23M 0.07% 286

Other funds holding HUM

Vident Advisory's HUM Position: Q2 2026 in Review

Vident Advisory reduced its Humana (HUM) stake by 2.2% in Q2 2026, selling an estimated $31K and leaving 4,861 shares worth $1.93M. The position accounts for 0.01% of the portfolio, ranked #705.

Vident Advisory first reported a position in HUM in Q3 2023 and has held it in 12 quarters since. The position peaked at $2.31M in Q3 2023. 928 funds tracked by Wall St. Rank hold HUM as of Q2 2026.

  • Vident Advisory held 4,861 shares of Humana worth $1.93M as of Q2 2026.
  • Vident Advisory sold 109 Humana shares in Q2 2026, an estimated $31K.
  • Humana made up 0.01% of Vident Advisory's portfolio in Q2 2026, its #705 holding.
  • Vident Advisory first reported a position in Humana in Q3 2023 and has held it in 12 quarters since.
  • Vident Advisory's Humana position peaked at $2.31M in Q3 2023.
  • 928 funds tracked by Wall St. Rank held Humana as of Q2 2026.

Based on Vident Advisory's 13F filing for Q2 2026, filed 12 Aug 2026.